Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Production / Operations

Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update

By The Northwire Desk — AI Analysis Mar 03, 2026 · 08:01 TRIP · 0.015 Red Light Holland Corp.
TRIP · Price

Executive Summary

  • Red Light Holland reported unaudited Q3 2026 results, showing revenue of C$1.265 M (+8.3% YoY) and a cash balance of C$9.238 M.
  • Adjusted EBITDA loss widened to C$0.711 M (up 4.5% from the prior year), while G&A expenses fell 15.8% to C$1.199 M.
  • The company disclosed several operational updates, including a second 5 kg psilocybin shipment to partner Irvine Labs, cessation of shiitake mushroom production at its New Brunswick farm, and ongoing M&A discussions.

Key Details

  • Cash Position: End‑quarter cash C$9.238 M (down from C$10.226 M three months earlier).
  • Net Cash Use: C$0.989 M net outflow for the quarter (increase of C$1.493 M vs Q3 2025).
  • Revenue: C$1.265 M for Q3 2026, up 8.3% YoY.
  • Gross Profit: C$0.358 M (down 13.7% YoY).
  • G&A Expenses: C$1.199 M, down 15.8% YoY due to lower consulting, management, legal and professional fees.
  • Adjusted EBITDA Loss: C$0.711 M, a 4.5% increase in loss versus the same quarter last year.
  • Total Assets: C$18.200 M (down from C$19.018 M).

R&D & Partnerships

  • Irvine Labs received a second 5 kg shipment of natural psilocybin (Nov 2025), supporting expanded dehydration and packaging validation; product condition issues noted.
  • Ongoing discussions with Irvine Labs on commercial micro‑dosing capsule manufacturing for therapeutic markets.
  • Collaboration with Arizona State University’s Psychedelic Genome Project to study genetic influences on psilocybin response.

Commercial Operations

  • SR Wholesale (Netherlands): Continued growth, serving >125 retail stores despite slower tourism.
  • Albertsons Partnership: Expanded U.S. retail presence under Safeway banner; further talks ongoing.
  • Functional Mushroom Gummies: Health Canada‑approved product launched on Amazon, later removed; stability testing completed successfully.
  • Pilot with Real Canadian Superstore (RCSS): Launched gummies but no additional store rollout during the quarter.

Asset & Business Adjustments

  • Shut down shiitake mushroom production at AEM Farm (New Brunswick); assets (trolleys, tractor, mixer) being sold to repay creditors.
  • Advanced talks to sell 100 % of rights to farmland, plans and permits in Peterborough, Ontario for an estimated C$2.5‑2.6 M; no definitive agreement yet.

M&A Activity

  • Management actively evaluating strategic acquisition opportunities to bolster R&D focus; no commitments disclosed.

Notable Quotes

“We were encouraged to see sales return to normalized levels…most importantly, we continue to actively evaluate strategic M&A opportunities from a position of strength.” – Todd Shapiro, CEO & Director

“As we evolve into an R&D‑driven organization supported by a solid balance sheet, inbound interest for collaboration and capital is increasing, reinforcing our credibility in the sector.” – Todd Shapiro

Read the original news release →

More from Red Light Holland Corp.

Jun 18, 2026 · 09:02

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

Other Jun 08, 2026 · 07:31

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Other Jun 04, 2026 · 07:32

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings